Ischemia-Reperfusion Injury Research

Ischemia/Reperfusion (I/R) injury is defined as the cellular damage that results from a period of ischemia that is followed by the reestablishment of the blood supply to the infarcted tissue.Myocardial ischemia, also known as cardiac ischemia, is defined as the deprivation of oxygen and nutrients to the heart. This phenomenon occurs during a myocardial infarction, when an occlusive thrombus within a coronary artery prevents blood supply to the myocardium, but can also occur during cardiac surgery as a result of pharmacological intervention to temporarily stop the heart. Reperfusion restores blood supply to ischemic tissue, but this is paradoxically associated with further tissue damage.

Ischemia-Reperfusion Injury Research Products Targets

Products for Ischemia-Reperfusion Injury Research - Page 10

Cat.No. Product Name Information/Activity
BCN4037 Piplartine Piperlongumine is a natural alkaloid isolated from Piper longum Linn, possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines. Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway.
BCN2586 Plumbagin Plumbagin (2-Methyljuglone) is a naphthoquinone isolated from Plumbago zeylanica L, exhibits anticancer and antiproliferative activities.
BCC3848 Rifaximin (Xifaxan) Rifaximin(Xifaxan) is an orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity.
BCN3834 Streptozotocin Streptozocin is a potent DNA-methylating antibiotic. Streptozotocin causes methylation of liver and kidney and pancreatic DNA, but no methylation in brain DNA.
BCC4386 Temozolomide Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects.
BCC2005 Toceranib Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors.
BCC2257 TW-37 TW-37 is a potent Bcl-2 inhibitor with Ki values of 260, 290 and 1110 nM for Mcl-1, Bcl-2 and Bcl-xL, respectively.
BCC2404 NQDI 1 NQDI-1 inhibits apoptosis signal-regulating kinase 1 (ASK1) with a Ki of 500 nM and an IC50 of 3 μM.
BCC6301 TC ASK 10 TC ASK 10 (Compound 10) is a potent, selective and orally active apoptosis signal-regulating kinase 1 (ASK1) inhibitor with an IC50 of 14 nM. The inhibitory activities of TC ASK 10 towards other representative panel of kinases are less than 50%, except for ASK2 (IC50 of 0.51 μM).
BCC2391 ARRY 520 trifluoroacetate Potent and selective kinesin spindle protein (KSP) inhibitor; induces Mcl-1 degradation,ARRY-520 is a synthetic kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM.